Loading...
CStone Pharmaceuticals
CSPHF•PNK
Healthcare
Biotechnology
$0.63
$0.00(0.00%)
CStone Pharmaceuticals (CSPHF) Financial Performance & Income Statement Overview
Review CStone Pharmaceuticals’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-12.21%
↓ 12.21%
Operating Income Growth
82.85%
↑ 82.85%
Net Income Growth
75.16%
↑ 75.16%
Operating Cash Flow Growth
100.00%
↑ 100.00%
Operating Margin
-50.50%
↓ 50.50%
Gross Margin
69.64%
↑ 69.64%
Net Profit Margin
-17.81%
↓ 17.81%
ROE
-14.42%
↓ 14.42%
ROIC
-25.22%
↓ 25.22%
CStone Pharmaceuticals (CSPHF) Income Statement & Financial Overview
Review CStone Pharmaceuticals's (CSPHF) income statement with detailed quarterly and annual figures.
Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
---|---|---|---|---|
Revenue | $76.52M | $76.52M | $127.08M | $127.08M |
Cost of Revenue | $42.46M | $42.46M | $41.07M | $41.07M |
Gross Profit | $34.06M | $34.06M | $86.01M | $86.01M |
Gross Profit Ratio | $0.45 | $0.45 | $0.68 | $0.68 |
R&D Expenses | $34.20M | $34.20M | $33.12M | $33.12M |
SG&A Expenses | $51.07M | $51.07M | $54.72M | $54.72M |
Operating Expenses | $85.27M | $85.27M | $87.84M | $87.84M |
Total Costs & Expenses | $127.73M | $127.73M | $128.91M | $128.91M |
Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
Depreciation & Amortization | $4.73M | $3.44M | $3.44M | $3.44M |
EBITDA | -$41.12M | -$42.41M | $1.61M | $1.61M |
EBITDA Ratio | -$0.54 | -$0.55 | $0.01 | $0.01 |
Operating Income | -$51.21M | -$51.21M | -$1.83M | -$1.83M |
Operating Income Ratio | -$0.67 | -$0.67 | -$0.01 | -$0.01 |
Other Income/Expenses (Net) | -$2.24M | -$2.24M | $9.68M | $9.68M |
Income Before Tax | -$53.45M | -$53.45M | $7.85M | $7.85M |
Income Before Tax Ratio | -$0.70 | -$0.70 | $0.06 | $0.06 |
Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
Net Income | -$53.45M | -$53.45M | $7.85M | $7.85M |
Net Income Ratio | -$0.70 | -$0.70 | $0.06 | $0.06 |
EPS | -$0.04 | -$0.04 | $0.005 | $0.005 |
Diluted EPS | -$0.04 | -$0.04 | $0.006 | $0.006 |
Weighted Avg Shares Outstanding | $1.28B | $1.28B | $1.57B | $1.57B |
Weighted Avg Shares Outstanding (Diluted) | $1.28B | $1.28B | $1.28B | $1.28B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan